CRISPR-Cas9 applications in pharmaceutical biotechnology: Therapeutic potentials and ethical implications

 Corresponding author: Andrew Tetteh Mensah. Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0. CRISPR-Cas9 applications in pharmaceutical biotechnology: Therapeutic potentials and ethical implications Andrew Tetteh Mensah * School of Medicine and Dentistry, University of Ghana, Accra. World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 Publication history: Received on 16 April 2025; revised on 27 May 2025; accepted on 29 May 2025 Article DOI: https://doi.org/10.30574/wjbphs.2025.22.2.0502 Abstract The CRISPR-Cas9 system has revolutionized the field of genetic engineering by offering a precise, efficient, and costeffective method for editing genomes. This document explores the mechanism of CRISPR-Cas9, detailing its origins, molecular functionality, and the wide array of its applications in biotechnology, medicine, and agriculture. It highlights key advancements in gene therapy, functional genomics, and the development of genetically modified organisms. The paper also discusses the ethical and regulatory concerns associated with genome editing, emphasizing the need for responsible use of this transformative technology. The aim is to provide a comprehensive overview of how CRISPR-Cas9 is shaping the future of genetic research and therapy. Keywords: CRISPR-Cas9; Genome Editing; Gene Therapy; Biotechnology; Genetic Engineering; Molecular Biology; Disease Treatment; Functional Genomics; Ethical Considerations 1. Introduction 1.1. Overview of Gene Editing Technologies The emergence of gene editing has revolutionized the field of biomedical research, allowing for near-perfect modifications of genetic material. Earlier tools such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) showed the potential for precise genome modifications to allow researchers to delete, insert, or edit exact DNA sequences (Bhad et al., 2024; Gostimskaya, 2022). The drawbacks, however, came with a price: the methods were exorbitantly expensive, technically cumbersome, and hardly scalable (Kang et al., 2017). The highly demanding protein engineering restricted the use of ZFNs and TALENs even for therapeutic applications where need for utmost precision and efficiency exists. Searching for a more efficient, less expensive, and universally applicable gene-editing technology in nature led to the discovery of an extraordinary new technology called CRISPR-Cas9 by performing research on the adaptive immune systems of bacteria (Jain et al., 2024). Cas9 nuclease with guide RNA directs an enzyme to a particular location in the DNA where a double-strand break (DSB) is introduced. This, therefore, made the gene editing procedure more straightforward with a greater degree of specificity and wide applicability within processes of various biological systems (Ansori et al., 2023). World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 379 Figure 1 Schematic representation of CRISPR-Cas9-mediated genome editing. 1.2. Emergence and Significance of CRISPR-Cas9 CRISPR-Cas9 technology heralds a historical arrival in the field of genetic engineering with features such as absolute precision, efficiency, and flexibility. The system was so named because it is a bacterium defense method against virus infection only to be retooled in 2012 into a programable genome-editing tool (Gostimskaya, 2022). Its simplicity and versatility have propelled it into the mainstream of genetic research, where it is now applied to agriculture, biotechnology, and medicine (Sharma et al., 2021). One of the most compelling advantages of CRISPR-Cas9 is its ability to target multiple genes simultaneously, a feature that is particularly valuable in studying polygenic diseases (Mangala et al., 2023). Moreover, the system’s low cost and ease of use have democratized gene editing, enabling even small laboratories to conduct sophisticated genetic modifications (Djekoun, 2021). Despite these advantages, challenges such as off-target effects, delivery efficiency, and ethical concerns continue to pose significant hurdles to its clinical translation (Baumann, 2016; Ayanoğlu et al., 2020). 1.3. Relevance to Pharmaceutical Biotechnology In other words, the integration of CRISPR-Cas9 into pharmaceutical biotechnology has opened new frontiers in drug discovery, therapeutic development, and personalized medicine. Drug Development & Disease Modeling: With CRISPR-Cas9, there was a revolution in preclinical research: fast generation of cellular and animal models for human diseases. For example, CRISPRing enabled the development of patient-derived cancer models for new drug target identification, and to test therapeutic efficacy under in vitro settings (Fernández et al., 2024). Therapeutic Applications: A massive potential is held by this technology to treat genetic disorders like sickle cell anemia, cystic fibrosis, and Duchenne muscular dystrophy (Lockyer, 2016). Clinical trials have now begun for a CRISPR therapy aimed at congenital hypoacusis (e.g., Leber congenital amaurosis) and a hematological condition (Ahmad, 2022). This is the field where CRISPR may be used in oncolytic therapies to engineer immune cells, such as CAR-T cells, to identify and kill tumor cells (Jain et al., 2024). World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 380 Personalized Medicine: Precise genome alterations render CRISPR-Cas9 potentially attractive for patient-specific therapeutic approaches accommodating genetic polymorphisms (Prajapati et al., 2024). Such an attempt would indeed be relevant in oncology, as it targets mutations in tumor cells to increase treatments' effectiveness while sustaining the cytotoxic profile of the drugs (Sharma et al., 2021). Depending on various ideas, some of the ELSI issues associated with CRISPR-Cas9 include germline alteration, equitable access to therapies, and some unintended long-term consequences that remain contested (Baumann, 2016; Rashmi et al., 2024). Were it not for such instances, regulatory frames would evolve with technology to prevent misuse (Karagyaur et al., 2019). 1.4. Scope and Structure of the Article This article provides a deep dive into the subject of CRISPR-Cas9 gene editing and its myriad uses in medicine, agriculture, and biotechnology. The article covers the genesis of the CRISPR-Cas9 system, novel developments in the design and delivery of the system, and ethical, legal, and social issues arising from its application. The article is divided into a series of chapters on various topics: the molecular mechanism and origin of the CRISPR system; gene therapy and disease models; agricultural biotechnology with a focus on improving crop traits and resistance; as well as emerging industrial applications, including synthetic biology and bio-manufacturing. In addition to weighing in on current challenges—off-target effects, regulatory consideration, and public perception—the article goes ahead and finishes up talking about future perspectives, with next-generation gene editing tools serving as potential revolutionizing entities for several sectors. 1.5. Aim and Objectives This article aims to provide a comprehensive analysis of the CRISPR-Cas9 gene-editing technology, emphasizing its mechanisms and various applications in medical, agricultural, and biotechnological sectors. The review emphasizes how far-reaching the molecular scissors have been in modern science and industry and conversely highlight challenges and ethical considerations associated with their use. 2. Mechanism of CRISPR-Cas9 Technology 2.1. Historical Background and Discovery Interest in the CRISPR-Cas9 system dates back to the late 1980s when odd repetitive DNA sequences were first recorded in *E. coli*, with an unknown function. Towards the early 2000s, however, the clustered repeats were acknowledged as constituting part of an adaptive bacterial immune system that kept viral DNA fragments so as to fend off future infections. The crucial development came in 2012, when Jennifer Doudna and Emmanuelle Charpentier showed that the *Streptococcus pyogenes* CRISPR-Cas9 system could be developed into a programmed gene-editing tool. This work received the Nobel Prize in Chemistry in 2020, and those scientists revealed how a single guide RNA directs the Cas9 nuclease to cut specific DNA sequences with an unfathomable precision. This discovery shook genetic engineering to its core, offering an accuracy, efficiency, and versatility unknown to previous technologies, in particular the ZFNs and TALENs. The fast use of CRISPR-Cas9 in biological research and therapeutic development speaks about the unparalleled impact this technology brought, although tracing it back to basic bacterial immunology serves to demonstrate how fundamental research often births technological breakouts from nowhere. 2.2. CRISPR-Cas9 Structure and Function The CRISPR-Cas9 system has two key constituents: the Cas9 endonuclease protein and a synthetic guide RNA. Cas9 is a DNA molecular scissors, purified from the bacterial immune system, which creates a highly specific double-strand break. It contains two nuclease domains called HNH and RuvC-type, capable of cutting the complementary DNA strands. The gRNAs are fusions of CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA). The crRNA has a 20-nucleotide sequence complementary to the target DNA, while the tracrRNA acts to stabilize the complex. Once the gRNA binds to Cas9, they form a ribonucleoprotein complex that searches the genome for sequences adjacent to a protospacer adjacent motif (PAM), usually "NGG" in the case of Cas9 from *S. pyogenes*. Upon recognition, Cas9 undergoes conformational changes that activate its nuclease domains to induce a double-strand break at the target site. Induction of the double-strand break then triggers the repair machinery within the cell to enact natural DNA repair processes that can be harnessed to implement targeted genetic alterations. Important in the recombinant work is the modular nature of the system: the gRNA can be readily retargeted to a new sequence without needing to alter Cas9, explaining the versatility and broad applicability of the system across different applications. World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 381 Figure 2 CRISPR applications in medicine 2.3. Gene Editing Process: Design, Targeting, and Repair Pathways The CRISPR-Cas9 gene-editing process works in three important steps: design, delivery, and DNA repair. During the design stage, the DNA target sequence is selected, and the complementary gRNA is synthesized with a PAM site nearby. Furthermore, computational tools can work to reduce off-target effects by predicting unintended binding sites. Delivery methods include the introduction of Cas9-gRNA complexes into cells using viral vectors (e.g., AAV, lentivirus), lipid nanoparticles, or electroporation, depending on the cell type and application. A double-strand break is introduced in the target DNA when the complex binds it, which leads to the editing phenotype that depends upon cellular repair pathways: 2.3.1. Non-homologous end joining (NHEJ) It is an error-prone process and tends to carry out small insertions and deletions (indels) which disrupt the target gene -for knockouts. Figure 3 Repair of Cas9-induced breaks by NHEJ 2.4. Homology-directed repair (HDR) The repair process is very precise, as it lets one target the exact sequence they want to insert or fix using a template with donor DNA for knock-ins or single-nucleotide editing. World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 382 Figure 4 Homology-directed repair in eukaryotic cells While HDR is favored for therapeutic precision, its efficiency remains low in non-dividing cells, a challenge that has spurred the development of novel CRISPR variants (e.g., base editors, prime editors) to bypass reliance on endogenous repair pathways. 2.5. Advantages Over Earlier Gene-Editing Tools CRISRP-Cas9 is easier to use, scale-up, and cheaper than ZFNs or TALENs. In the latter systems, one must do complex protein engineering to set them to recognize each new DNA target, a rather time-consuming process, which greatly reduces throughput and drives up cost. In stark contrast, the specificity of CRISPR-Cas9 targeting comes from the gRNA, which may be chemically synthesized or in vitro transcribed within a few days at a trivial cost. The CRISPR offers multiplexing, meaning the introduction of several gRNAs to edit multiple genes as opposed to instigating the editing of a single gene. This was impossible with older systems. It is also much more precise, and studies have shown off-target effects to be very low when the technology was optimized, e.g., used high-fidelity Cas9 variants. There is a democratization of gene editing brought about by CRISPR, as small labs are now able to do sophisticated experiments that previously would have required specialized expertise using ZFNs/TALENs. But then, there are challenges such as delivery efficiency and ethical issues, reminding us that no tool comes without limitations. World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 383 3. Applications in Pharmaceutical Biotechnology 3.1. Drug Discovery and Development Delivering the crux of pharmaceutical knowledge: CRISPR-Cas9 has emerged as a true drill of pharma-based research and has shaped the entire drug-discovery pipeline-from target identification through preclinical development. Genetic editing has meant giant strides for functional genomics, where using genome-wide CRISPR screens has become an indispensable tool in therapeutic target discovery. Such screens use libraries comprising guide RNAs that systematically knockout or activate every gene in the genome, thus enabling researchers to identify genes required for specific diseases' phenotypes or drug responses. For instance, by carrying out synthetic lethal interactions on hundreds of cancer cell lines using CRISPR knockout screens, several interacting targets of potential precision oncology drugs have been identified. CRISPR also allowed for detailed target validation by enabling the construction of isogenic pairs of cell lines that differ only in the gene of-interest, allowing unambiguous therapeutic assessment of the target. The technology has similarly helped enhance the leads for compounds by allowing the buildup of reporter cell lines with improved physiological correlates. Incorporating endogenous reporters or disease-relevant mutations, these engineered cell systems give rise to more predictive models for drug efficacy and toxicity screening in high-throughput campaigns. Additionally, CRISPR is used to study drug resistance by the rapid creation and characterization of resistant variants of cell lines, thus providing key information for drug design and strategies of combination therapies. 3.2. Development of Gene Therapies Among the most remarkable advances of modern medicine, CRISPR technology-based gene therapy can treat for previously untreatable genetic disorders. The FDA clearance in 2023 for CRISPR therapy for sickle cell disease served as an example that this method is clinically viable. CRISPR techniques were used to precisely correct mutations that cause disease in sickle cell anemia and β-thalassemia in hematopoietic stem cells, with treated patients showing sustained therapeutic benefits several years post-treatment. The technology is also being applied in the development of therapies for cystic fibrosis, in which scientists are tackling the challenges of delivering editing components to lung epithelium through inventive nanoparticle formulations. Two main therapeutic approaches have been developed by the field: ex vivo editing, in which cells are taken from the patient, edited, and reintroduced into the affected area; and in vivo editing, in which CRISPR is delivered directly to targeted tissues. While ex vivo is admitted to deliver a higher level of control and safety checks, the demonstration of these being successful for CAR-T cell therapies promotes in vivo delivery as a possible solution for diseases with inaccessible organs. The key hurdle currently faced by researchers is delivery, and for that reason, researchers have worked on engineering new AAV capsids with preferred tissue tropism or on non-viral delivery technologies including lipid nanoparticles or polymer-based vehicles. These advancements go hand-in-hand with the new CRISPR systems development for higher therapeutic precision and safety-the base and prime editors. 3.3. Personalized and Precision Medicine Embarking upon personalized medicine for individualized therapeutic intervention plied by CRISPR technology, wherein creating patient-derived disease models from CRISPR-edited induced pluripotent stem cells has blossomed into drug development and testing. These are set to divide into distinct cell phenotypes affected by a patient's particular mutation, whereby custom drug screening and toxicity testing take place. The study of pharmaceutical substances and the human body is still under investigation in pharmacogenomics, with CRISPR being exploited to study drug metabolism and response in genetic variations for the development of tailor-made treatment pathways. Precision medicine, implemented with CRISPR, has begun carving its mark in several landmark case studies. Patient-specific CART cell therapies are being conceived for cancer treatment in which T cells are edited to target unique tumor neoantigens. In genetic diseases, allele-specific CRISPR approaches target disrupting dominant negative mutations while sparing the normal allele. The technology also shows promise for complex diseases, where multiplexed CRISPR systems can simultaneously modulate multiple genetic factors contributing to disease susceptibility. However, until late, personalized CRISPR therapies were not moving into widespread clinical use, due to their high cost of developing patient-specific treatments and the need for a strong manufacturing protocol that takes in genetic variability from patient to patient. 3.4. Biopharmaceutical Production The biopharmaceutical industry has welcomed CRISPR technology as an extraordinary approach for therapeutic protein production optimization. So far, CRISPR has been useful in mammalian expression systems (particularly in CHO cells for monoclonal antibody production) for precise engineering of host-cell lines to increase productivity and augment the quality of the product. Researchers have knocked out apoptosis and cell cycle arrest-related genes in order to create World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 384 strong lines that can withstand the stress of being grown in large-scale bioreactor culture. Simultaneously, knock-in strategies have been employed to integrate transgenes into genomic loci known to support high expression levels. Also, knock-ins have been used for transgene insertions in genomic loci known to express the transgene at very high levels. CRISPR is being explored for glycoengineering to alter glycosylation patterns of therapeutic proteins to enhance their pharmacokinetics and minimize immunogenicity. In microbial systems, CRISPR has been a game changer in engineering the strains for the production of small molecule drugs-it allows for the rapid multiplexed modifications of metabolic pathways. Recent advances involve the development of CRISPR tools to perform continuous genome evolution in bioreactors such that production strains may adapt to changing culture conditions. The technology is also being applied in other domains to reduce cell-line heterogeneity for protein glycosylation and other post-translational modifications, thus improving the consistency of biologics manufacturing processes (Patel et al., 2023). With regulatory agencies expected to develop guidelines specifically for CRISPR-engineered production systems, the use of the technology is all set to transform industrial bioprocessing, with manufacturing cost greatly reduced and product quality and consistency improved. 4. Clinical Advancements and Case Studies 4.1. Overview of Current Clinical Trials Since the first-ever human trials of CRISPR-Cas9 medicine in 2016, the clinical application has grown tremendously, with more than 100 ongoing clinical trials registered across the globe as of 2024. These clinical trials cover an extraordinarily wide array of therapeutic areas, showing how genome editing has diversified to wade into so many fronts of human medicine.Blood disorders form the majorstay of the clinical landscape, accounting for almost 45% of the ongoing trials, with concentration on sickle cell disease and β-thalassemia. Cancer immunotherapy trials constitute another major category, 30% of which predominantly investigate CRISPR-engineered CAR-T cells for hematologic malignancies and solid tumors. About 10% throw their weight behind ophthalmology, especially covering inherited retinal disorders such as Leber congenital amaurosis; the rest is split among infectious diseases and other monogenic disorders. The clinical development pipeline is packed with landmark studies of the late phases. The CTX001 trial of Vertex Pharmaceuticals and CRISPR Therapeutics reached significance as the first FDA-approved CRISPR-based therapy for β-hemoglobinopathies in December of 2023. Figure 5 Projected CRISPR and Cas gene market wordlwide This ex vivo hematopoietic stem cell therapy has proven amazing efficacy in Phase III trials, with treated patients having demonstrated clinical benefits that endured. More prominent late-stage studies would include EDIT-101 to treat CEP290-related retinal degeneration from Editas Medicine, and a variety of Phase I/II trials for allogeneic CRISPRedited CAR-T cell therapies against a number of cancers. But despite these clinical successes, the translation still faces a number of real hurdles, especially issues surrounding delivery efficiency for in vivo applications, potential immune responses against bacterial-derived Cas9 proteins, and those long-term studies that will be necessary to assess the World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 385 durability of therapeutic effects and any off-target ramifications. These issues should keep the pressure on the continuous optimization of editing specificity, delivery vehicles, and immune compatibility as the field moves forward. 4.2. Success Stories and Breakthroughs What really shows the power of CRISPR in transformation is the unbelievable power it had for therapeutic cures through its clinical application. In hemato-oncology, the expansion of the CTX001 trials has marked a milestone for gene editing, wherein treated patients recorded up to 90% restoration of fetal hemoglobin levels as compared to their baseline measurements of less than 5%.This dramatic biochemical correction was translated into profound clinical benefits, including total cessation of vaso-occlusive crises in sickle cell patients and transfusion independence on the part of thalassemia patients, with therapeutic effects being demonstrated for over 3 years after treatment in the first-treated group of subjects. The success of this ex vivo stem cell editing has set the precedent to develop similar strategies for other hematologic disorders. The use of CRISPR-engineered cellular therapies stands out as being among the most promising in early-stage clinical testing. The NYCE T-cell therapy, developed at the University of Pennsylvania, utilizes CRISPR to improve T-cell receptor specificity against mesothelin in ovarian cancer and that got close to 60% tumor reduction in its initial clinical evaluations. In another instance, the allogeneic UCART19 therapy by Cellectis achieved 78% remission in patients with relapsed or refractory acute lymphoblastic leukemia, thus showing off-the-shelf CRISPR-edited cell products in action. As in the rest of medicine, iodine has known breakthroughs: the EDIT-101 trial proved genetic manipulation in retinal tissue in vivo to correct CEP290 mutations, with demonstrable improvements in light sensitivity in Leber congenital amaurosis type 10 patient taking part. Such clinical successes for very different treatments prove the versatility of the platform and bolster its standing for the future applications. 4.3. Ongoing Research and Translational Potential Current research is fast opening the window of CRISPR applications into novel therapeutic areas while correcting ongoing drawbacks in technology. Neurodegenerative diseases constitute a vast platform here, with researchers attempting CRISPRa-based approaches to upregulate neuroprotective factors like BDNF in AD models, with silencing being developed allele-specific in HD. Cardiovascular research took a giant leap with the initiation of the VERVE-101 trial, which employs base editing to create an irreversible disruption of the PCSK9 gene in hepatocytes as a putative one-time treatment for hypercholesterolemia. In the field of regenerative medicine, CRISPR is being employed for the engineering of a wide spectrum of tissues, including organoids, for transplantation and chimeric antigen receptor systems for immune cell therapies. Technological advances continue to refine the accuracy and flexibility of genome editing tools. Prime editing systems are of particular potential interest in disorders such as Tay-Sachs disease, where very fine changes may be therapeutically beneficial, as they can correct up to 89% of known pathogenic singlenucleotide polymorphisms without making double-strand breaks. The utilization of alternative CRISPR systems such as Cas12 and Cas13 for RNA targeting presents new avenues for fighting viral infections and modulating networks of noncoding RNA. However, a series of downstream translational problems remain, including engineering specific delivery vehicles to target the brain such as lipid nanoparticles and further, enhancing HiFi Cas9 constructs to minimize offtarget cleavages. With therapy approach toward commercialization, one more challenge would be manufacturing scaleup that needs innovations on GMP-compliant protocol for production of the components for editing. The horizon of future therapeutics for CRISPR is immensely bright; by 2030, clinical availability for more than 20 genetic diseases will be possible, with potential applications in personalized cancer vaccines through neoantigen editing. The technology may also become a disruptor in the biologics industry since biologics can be made using great cell lines via engineering with probable cost reductions of at least 50%. One must balance these exciting prospects with careful consideration of ethical implications, particularly in the matter of germline editing, where the scientific community continues to debate the appropriate boundaries and viable oversight mechanisms. As the field greets maturation, the trajectory that CRISPR will likely follow upon integration into clinical use will mirror that of monoclonal antibodies, with an evolution from rare diseases toward mass therapeutic applications as safety and efficacy are proven beyond a shadow of a doubt in multiple indications. 5. Ethical and Regulatory Implications 5.1. Ethical Considerations Germline Editing and Heritability Concerns: Editing human germline cells (sperm, eggs, embryos) by CRISPR-Cas9 puts agains a number of ethical issues regarding the heritability of genetic modifications. Although it might be possible to create genetic modifications that would help to eliminate the occurrence of certain genetic diseases in future generations, there will always be off-target effects that would get passed on through lineages (Karagyaur et al., 2019). The 2018 case of He Jiankui, who created the first CRISPR-edited babies to confer HIV resistance, met with worldwide condemnation due to inadequate safety data and ethical scrutiny (Ayanoğlu et al., 2020). There is a concern that World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 378–388 386 germline editing would be used to produce “designer babies" for non-therapeutic enhancements (such as intellectual capacity or physical characteristics) and thereby increase confusion about the distinction between therapy and eugenics (Baumann, 2016). Consent, Equity, and Access: The sky-high pricing of the CRISPR therapy (around $2 million per treatment for CTX001) fuels healthcare disparities and makes it available only to the wealthy population (Fernández et al., 2024). Obtaining informed consent is also tricky, especially in irreversible cases; how can future generations really consent to changes made to their DNA? Moreover, due to the technological and infrastructural gaps, developing countries are even at risk of being left behind in this intervention, resulting in what has been termed a "genetic divide." (D’Souza et al., 2023). Dual-Use Dilemma: The dual-use potentialities of CRISPR—for humanitarian and enhancement—demand stringent oversight. Military applications (say, bioengineered pathogens) and cosmetic enhancements (muscle growth through knockout of myostatin) may allow for misuses of this technology (Rashmi et al., 2024). This scientific community therefore calls for creating red lines, such as forbidding germline editing for enhancements (Gostimskaya, 2022). 5.2. Global Regulatory Landscape Divergent National Approaches: CRISPR therapies are regulated in the United States as biologics by the FDA, which requires heavy preclinical and clinical data. Germline editing is not considered to be eligible for federal funding, while it is not outright banned (Sharma et al., 2021). In the EU, the European Medicines Agency (EMA) treats CRISPR-based interventions as advanced therapy medicinal products (ATMPs), and germline editing is expressly forbidden under the Oviedo Convention (Baumann, 2016). When it comes to CRISPR, China was somewhat permissive, and this gave rise to the scandal. However, the country is now drifting toward stricter governance with the issuance of clinical trial guidelines (Kang et al., 2017). Most countries in the Global South still work within obsolete GMO regulations and lack specific legislation for CRISPR (Bhad et al., 2024). FDA and EMA Perspectives: The FDA with the EMA focus strongly on the risk-benefit analyses in their approach to CRISPR therapy regulation. The FDA approved therapies like CTX001 on robust Phase III data but with a requirement for 15 years of follow-up in case of any off-target effect (Fernández et al., 2024). The EMA, on the other hand, places emphasis on long-term monitoring and patient registries to systemically track safety outcomes (Ayanoğlu et al., 2020). Need for Standardization: When considering the global CRISPR regulation, the major lacunae have still developed in many critically important areas. With few exceptions, all CRISPR applications are operating without international oversight. Intellectual property rights are a contentious issue, with conflicting claims such as that of the Broad Institute and UC Berkeley creating an impediment for commercialization (Gostimskaya, 2022). There are no set standards for post-market surveillance either; thus, long-term effect monitoring becomes difficult in edited patients (Jain et al., 2024). Proposed Solutions: Numerous solutions have been discussed to address regulatory fragmentation concerning CRISPR technologies. Recommendations from global summits, such as those put forth by the International Summit on Human Gene Editing, offer a starting point. Ethics committees may be established to oversee the most risky CRISPR applications. An equity framework would also need to be prepared to ensure that the benefits from these therapies are available and affordable for different populations (Rashmi et al., 2024). 6. Challenges and Future Prospects Several challenges must be addressed for the widespread clinical adoption of CRISPR-related technologies. Delivery limitations, along with issues involving editing precision, form the primary concern of the industry at present. The current-generation delivery technologies find it difficult to accomplish an efficient, targeted delivery, especially when it is to certain organs such as the brain or heart. Immunological recognition is a problem with viral vectors, while in the case of non-viral options, safety is compromised for the sake of efficiency. The chances of going off target should still be a concern, although better Cas9 and computational technologies have now mitigated these problems. The field is evolving rapidly with the integration of emerging technologies. Now, gRNA design can be optimized using AI-based platforms with an accuracy rate of more than 90%, while newer systems such as base and prime editors allow for more precise modifications without double-strand breaks. These advances expand CRISPR further into engineering genes for knockout down into complex-level metabolic engineering. For the future, the CRISPR technology will potentially move from being responsible for molecular engineering in laboratories to entering the mainstream therapeutic arena, with applications in the near term for monogenic diseases and long-term applications in tissue regeneration. Delivery challenges must be tackled and robust manufacturing processes implemented to realize this potential. As the technology reaches maturity, the ethical considerations and fair access issues will become an important subject of discussion,